Hosted on MSN1mon
V.MDCX: Medicus Pharma Has Begun Trading on Nasdaq under the ticker MDCX after Completing an IPO in the U.S. The SKNJCT-003 Phase 2 clinical trial continues.
Utilizing a financial model based on DCF methodology, which forecasts out to 2031 and uses a 12% discount rate (based on CAPM), and a terminal P/S multiple of 2.79 (based on Specialty Drug ...